Infections in biological and targeted synthetic drug use in

2 rheumatoid arthritis: where do we stand? A scoping review and

3 meta-analysis

1

4

7

19

23

- 5 Bergmans, BJM (1,2)*; Gebeyehu, BY (1,3); van Puijenbroek, EP (4,5); Van Deun, K (3);
- 6 Kleinberg, B (3); Murk, JL (2,6); de Vries, E (1,2)
- 8 Affiliations
- 9 1 Tranzo, Tilburg School of Social and Behavioral Sciences, Tilburg University, Tilburg,
- 10 The Netherlands
- 11 2 Department of Medical Microbiology and Immunology, Elisabeth-TweeSteden Hospital,
- 12 Tilburg, The Netherlands
- 13 3 Department of Methodology and Statistics, Tilburg School of Social and Behavioral
- 14 Sciences, Tilburg University, Tilburg, The Netherlands
- 15 4 Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands
- 16 5 University of Groningen, Groningen Research Institute of Pharmacy, PharmacoTherapy, -
- 17 Epidemiology & -Economics, Groningen, The Netherlands
- 18 6 Microvida, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands
- 20 * Corresponding author
- 21 b.j.m.bergmans@tilburguniversity.edu
- 22 Postbus 90153, 5000 LE Tilburg

Abstract

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

Objectives: The advent of biological and targeted synthetic therapies has revolutionised rheumatoid arthritis (RA) treatment. However, this has come at the price of an increased risk of infections. The aim of this study was to present an integrated overview of both serious and non-serious infections, and to identify potential predictors of infection risk in RA patients using biological or targeted synthetic drugs. Design: We systematically reviewed available literature from PubMed and Cochrane and performed multivariate meta-analysis with meta-regression on the reported infections. Randomised controlled trials and prospective and retrospective observational studies including patient registry studies were analysed, combined as well as separately. We excluded studies focusing on viral infections only. Results: Infections were not reported in a standardised manner. Meta-analysis showed significant heterogeneity that persisted after forming subgroups by study design and followup duration. Overall, the pooled proportions of patients experiencing an infection during a study were 0.30 (95%CI, 0.28-0.33) and 0.03 (95%CI, 0.028-0.035) for any kind of infections or serious infections only, respectively. We found no potential predictors that were consistent across all study subgroups. **Conclusions**: The high heterogeneity and the inconsistency of potential predictors between studies show that we do not yet have a complete picture of infection risk in RA patients using biological or targeted synthetic drugs. Besides, we found non-serious infections outnumbered serious infections by a factor 10:1, but only few studies have focused on their occurrence. Future studies should apply a uniform method of infectious adverse event reporting and also focus on non-serious infections and their impact on treatment decisions and quality of life.

Keywords

50

- 51 Biological, infection, heterogeneity, meta-analysis, meta-regression, rheumatoid arthritis,
- 52 targeted synthetic drugs,

Introduction

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

Patients with rheumatoid arthritis (RA) have an increased risk to contract serious infections which are defined as infections that are life-threatening or fatal, result in significant disability or require hospitalization[1, 2]. Aside from RA itself, which impairs an effective immune response to pathogens [3], the immunomodulating therapies used to treat RA also contribute to this risk. Biologicals are monoclonal antibodies that target essential components in immune pathways related to RA pathogenesis. TNF-alpha inhibitors were introduced first, in the late 90's (infliximab, etanercept, adalimumab, certolizumab pegol, golimumab). Other biologicals soon followed: anti-CD20 (B-cell) agents (rituximab), T-cell co-stimulation inhibitors (abatacept) and interleukin-(IL)-antagonists (most notably tocilizumab (anti-IL6) and anakinra (anti-IL1)). Existing categories are still expanding, and many other biological classes are investigated as potential RA treatments. Targeted synthetic drugs are the most recent addition to the RA treatment options. These are small molecules that inhibit proinflammatory cytokine production through interference with intracellular signalling pathways, for example Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) inhibitors (tofacitinib, filgotinib). Most RA patients need a combination of different immunomodulators to adequately control their RA. The current knowledge on infectious adverse events following treatment of RA with biologicals originates from several study designs, each with their own strengths and weaknesses[4]. Initially, infectious adverse events were mainly reported in randomised controlled trials (RCTs), which are limited by a relatively short follow-up and the employment of exclusion criteria, such as serious comorbidities or recurrent infections. Post-

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

marketing observational studies may have a longer follow-up and include patients that would be considered ineligible in RCTs, but generally focus on serious infections only. Case reports mostly describe (very) rare, serious infections which are likely to be missed in trials due to the shorter follow-up. A number of factors have been identified that increase the risk of serious infections in RA, most notably the presence of comorbidities such as diabetes mellitus and cardiovascular disease [5] [6], longer RA disease duration[7], older age, extra-articular RA manifestations, a previous history of recurrent infections, higher disease activity[8-10] and corticosteroid use[3, 11]. Biological use is another risk factor. An increased rate of serious infections as compared to placebo has been reported for several biologicals[12]. Tuberculosis reactivation, for example, is a well-documented adverse effect of TNF-alpha inhibitor use[13-15]. Little attention has been paid to the specific types of infections or the occurrence of non-serious infections during biological therapy [16]. More detailed knowledge would enable clinicians to monitor patients more closely or even prevent infections. To perform a thorough analysis of infections in biological and targeted synthetic therapy use, we included as many study designs and as many articles as possible to be able to generate a complete overview. To this end, we performed a scoping review and meta-analysis with meta-regression taking disease characteristics, patient characteristics and comorbidities into account. We determined the pooled proportion of patients that experienced serious and/or non-serious infections during treatment with biologicals or targeted synthetic therapies included in trials, observational studies and registries. We compared this information with an overview of infections published in case reports of RA patients using biological or targeted synthetic therapies. In addition, we aimed to identify risk factors for developing these infections.

Materials and methods

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

We systematically collected available literature and performed a descriptive as well as metaanalysis with meta-regression following the PRISMA guidelines[17]. See S1 Appendix for the search terms and strategy. We aimed to include a wide variety of article types, as a complete overview of infections can only be obtained when analysing all available literature. Narrative reviews, meta-analyses, studies on other antirheumatic drugs, studies not reporting infectious complications, not reporting data on RA patients separately, focusing on postoperative complications, or aggregating results of different drug classes were excluded. We also excluded studies focusing on the coronavirus disease that emerged in 2019 (COVID-19) because the lockdowns created a unique situation of decreased exposure, and studies focusing on reactivating viral infections only, as they originate in a different epidemiological setting altogether. Only published, peer-reviewed articles published until January 10, 2021, written in English and collected from PubMed and Cochrane were included. This review was registered at the Open Science Framework (Registration DOI 10.17605/OSF.IO/FWTQE). Blinded study selection was performed using Rayyan software[18]. EdV, JLM and BB performed the title and abstract selection, JLM and EdV each evaluating half and BB all hits, in order to review each article twice. Discrepancies were resolved by discussion until consensus was reached. BB screened the remaining full-text articles (flowchart in S2 Appendix). We discussed beforehand which variables would be extracted (see S3 Appendix and S4 Appendix). Two databases were constructed: one for RCTs, RCTs with open label extension studies (RCT+OLE), prospective observational studies, registry studies, open label studies and retrospective observational studies, and one for the case reports and series.

Randomised controlled, prospective and retrospective

observational studies

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

Studies with multiple study arms examining multiple drugs, multiple different dosages of the same drug, or studies that reported the use of more than one observational study separately were divided into multiple entries in the database. Studies using the same registry or database, and RCTs and associated extension studies were critically reviewed and in- or excluded as described in S5 Appendix and S6 Appendix to prevent duplicate data. The following information was extracted per study (arm): year of publication, country of origin, biological or targeted synthetic agent name, class and dosage, follow-up duration, number of included patients, sex, age, and other patient characteristics, laboratory parameters, being: C-Reactive Protein (CRP) or Erythrocyte Sedimentation Rate (ESR), disease activity inventories (Disease Activity Score using CRP or ESR (DAS28-CRP/ESR), Clinical Disease Activity Index for RA (CDAI), Health Assessment Questionnaire - Disability Index (HAQ-DI), Swollen Joint Count in 66 joints (SJC66), Tender Joint Count in 68 Joints (TJC68), Patient's Global Assessment (Visual Analogue Scale 0-100), Physicians, Global Assessment (Visual Analogue Scale 0-100), Pain score (Visual Analogue Scale 0-100), Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-fatigue)) concomitant immunosuppressant use, concomitant Non-Steroidal Anti-Inflammatory Drug (NSAID) use, use of any prior conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) or biological/targeted synthetic therapies, presence of comorbidities, number and type of infectious events during follow-up, number of serious infectious events and rate of infectious events during follow-up (details in S3 Appendix).

Infection count was extracted either as the total number of infected *patients* in a population of *n* patients, the number of infectious *events* in a population of *n* patients, an incidence rate (*n* infected patients per 100 patients) or an event rate (*n* events per 100 patient-years of exposure to study drug), as reported in the original article. Infections were extracted as either the number and/or rate of the *total* number of infections, as stated by the authors, or the number and/or rate of *serious* infections, as stated by the authors. See table 1 for terms and definitions used throughout this paper. Specific infections were grouped into composite variables by the corresponding organ-system (see S7 Appendix). Information on the occurrence of *specific* infections was also extracted, if available, in the manner stated previously.

Table 1: terms and definitions used throughout this paper

Term	Definition
Serious infection	A serious adverse event[2] of infectious nature, as
	defined by the authors
Total number of infected patients	Total number of infected patients in the study as
	stated by the authors (a patient is counted only
	once even though she/he could have had multiple
	infections) including both serious and non-serious
	infections
Total number of seriously infected	Total number of patients in the study that
patients	experienced an infection considered serious, as
	stated by the authors (a patient is counted only
	once even though she/he could have had multiple
	serious infections)
Total number of infectious events	Total number of infectious events in the study as

	stated by the authors (a patient can be counted
	multiple times as she/he can experience multiple
	events), including both serious and non-serious
	infections
Total number of serious infectious	Total number of serious infectious events in the
events	study as stated by the authors (each event a patient
	experiences is counted, even if the patient
	experiences multiple serious events)
Incidence rate	The number of infected patients per 100 patient-
	years of follow-up
Event rate	The number of infectious events per 100 patient-
	years of follow-up

Case reports and series

Single case reports and case series from the literature search and from secondary citations were included. We analysed the case series as separate case reports (they contained 2-15 cases per article). Per case, the following information was registered in the database: country of origin, year of publication, patient characteristics (age, sex, comorbidities), time since RA diagnosis, prescribed biological/targeted therapy and duration of use, comedication, infectious diagnosis using Medical Dictionary for Regulatory Activities (MedDRA)[19] terminology, causative micro-organism, affected organ system, diagnostic method and outcome (details in S4 Appendix).

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

Statistical analysis Data analyses and visualizations were carried out using R (R Core Team, version 4.2.1, 2022-06-23) and RStudio (version 2021.9.1.372) with the packages metafor[20], dmetar[21] and ggplot2[22]. Randomised controlled, prospective and retrospective observational studies We estimated the pooled proportions of the total number of infected patients and the number of seriously infected patients with their 95% confidence intervals (CI) across all studies as well as grouped by study design and biological target. The majority of the studies included in this review contributed two or more study arms and therefore multiple proportions of infections. A multivariate meta-regression model was used to account for this potential dependence between proportions belonging to the same study. Raw proportions were transformed into logit transformed proportions (i.e., the log of the proportion divided by one minus the proportion). Logit transformation was selected for its straightforward backtransformation and to ensure the confidence interval estimates fell between 0 and 1[23]. Event rates per patient-year were also estimated for total and serious infection events using multivariate meta-regression. We used the rma.mv function of the metafor package[20] with the input of the observed effect sizes and the corresponding sampling variances; see S8 Appendix for details. The heterogeneity between the reported proportions and event rates was assessed by computing I^2 [24] and Cochran's generalized O test [25, 26]. The I^2 statistic describes the percentage of variation in the estimated effects that is explained by differences between the included studies rather than by chance. Similar to Higgins et al. [24], we categorised the level of heterogeneity based on I^2 as low (25% to 50%), moderate (50% to 75%), and high (≥75%). The Cochran's Q test statistic is the weighted sum of squared differences between

202

203

204

205206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

the observed effects and the overall effects and the pooled effect across studies. The null hypothesis of the test is that all studies have the same effect size, and the alternative hypothesis is that the effect size for at least one study is different. For the Cochran's generalized Q test, $p \le 0.05$ was regarded as significant heterogeneity. We followed a two-stage procedure to deal with heterogeneity, if present. In the first stage, we attempted to create mutually exclusive sets of studies that were relatively homogeneous. We grouped studies based on study design (RCT, retrospective study, RCT+OLE, prospective cohort study, registry, open-label trial) and follow-up length (δ18 weeks; 19-38 weeks; 39 – 60 weeks) (see S8 Appendix for details) and assessed the level of heterogeneity separately for each subgroup. In the second stage, a multivariate meta-regression was used to further identify factors that significantly moderated the observed heterogeneity. A common pitfall of meta-regression is the use of a small number of studies per examined covariate[27]. The Cochrane handbook suggests a minimum of 10 studies per covariate[28]. For our multivariate meta-regression model, we first identified potential moderators from the literature (see S9 Appendix for details). Then, all of these features that were reported by at least 10 studies were included in the model. Moderator analysis using multivariate metaregression was performed only for RCT studies as the number of studies per subgroup was below 10 for other study designs. In comparison, the multivariate meta-regression model was also fitted for alternative grouping of studies, separately for each study design (results see S10 appendix). We also created two composite features ourselves. The included studies used a selection of ten different disease activity indices (see above). Each study reported at least two of these indices, however, the specific indices that were used varied greatly across studies. A

composite disease activity was computed by scaling each disease activity index using each index's minimum and maximum values and then taking the mean of the scaled values (details in S11 Appendix). Out of all utilised exclusion criteria, we identified 14 unique ones that all studies used in varying combinations. To overcome this, we created a second composite variable: the summed number of exclusion criteria used in each study (details in S12 Appendix).

Case reports and series

- In the case reports database, patient characteristics, infection location and micro-organisms
- were analysed using descriptive statistics.

Results

Trials, registries and cohort studies

The final selection for this category yielded 242 studies containing 512 study arms and a total of 293,431 patients (descriptive statistics see S13 Appendix). The largest proportion of studies were RCTs (150, 61.9%), but the highest proportion of patients were supplied by registry studies (172,892 patients, 59%). A high proportion of studies was carried out in Western countries, with 182 (79%) studies taking place in North America and/or Europe (see S14 Appendix). Out of all studies reporting on race or ethnicity, 89% of participants was Caucasian. TNF-alpha inhibitors were the most often administered biological class, with 117 studies (44%), 205 study arms (42%) and 170,826 patients (58%). Most patients were female (79.0%). The weighted mean age was 57 years. No causative micro-organisms were specified in trials, registries, or cohort studies. There was a high variability in the methods of infectious adverse event reporting. These were not mutually exclusive, with 129 studies reporting a total

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

number of infected patients, 157 studies reporting a total number of seriously infected patients, 25 studies reporting the total number of infectious events and 38 studies reporting the total number of serious infectious events. Specific infections within the number of infected patients and number of infectious events were reported by 166 and 29 studies, respectively. Incidence and event rates were reported by a minority of studies, see S13 Appendix. Fig 1 shows the number of studies by study design and by biological target over the past three decades. Fig 1. Distribution of included studies by year of publication and study design (a) and by year of publication and biological target (b) JAK= Janus kinase, OLE= open label extension, RCT= randomised controlled trial, TNF= tumour necrosis factor. Between-study heterogeneity and subgroups The between-study heterogeneity was assessed first for all studies together, then for each study design separately, and finally by further grouping studies based on follow-up duration (see Fig 2). There was substantial between-study heterogeneity when all studies are taken together (both total as well as seriously infected patients). All subgroups based on study design - except the registry subgroup (which comprised only three studies) - showed significant heterogeneity. Following the pattern observed in the follow-up duration of studies (see S8 Figs 1 and 2), we defined three subgroups: \leq 18 weeks, 19-38 weeks, and 39-60 weeks. Although the level of heterogeneity was reduced after subgroups were formed, a moderate to higher level of heterogeneity remained, especially among subgroups for the total number of infected patients. For that, we employed a multivariate meta-regression model, see

S15 Appendix and S16 Appendix for the results.

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

Fig 2. Between-study heterogeneity metrics and subgroup formation I^2 = variation (%) explained by differences in studies, n= number of studies/study arms, σ_1^2 = variance (between-study), σ_2^2 = variance (within study), Q(P)= Cochran's Q test p-value. Overall, heterogeneity reduced sequentially as studies were grouped first based on study design (stage 2) then based on follow-up duration (stage 3). This was especially true for the number of seriously infected patients. Pooled proportion of infected patients and event rate estimates The estimated pooled proportions of the total number of infected patients and of the number of seriously infected patients were determined consecutively 1) across all study arms, 2) grouped by study design, and 3) grouped by biological/synthetic therapy target. Across all study arms, this comprised 58,789 (totally infected) and 168,042 (seriously infected) participants, as there were more studies reporting on serious infections only. There was considerable between-study heterogeneity, more so in the pooled proportion of the total number of infected patients than in the pooled proportion of seriously infected patients (Fig 3). The pooled estimates and heterogeneity metrics for both the proportion of infected patients and event rates are presented in table 2. In table 2, we presented results for the categories of biological target and study design that are reported by at least two studies ($n \ge 2$) as it is the minimum number (n) required to compute the pooled estimates using multivariate meta-regression. The estimated pooled proportion of the total number of infected patients was highest in RCT ± OLE and RCT studies. However, the differences between the estimated pooled proportions

must be interpreted with caution as the heterogeneity as well as the number of studies per design subgroup varied substantially. The estimated pooled proportion of seriously infected patients was highest in registry and retrospective studies; however, the heterogeneity was also highest in these two study designs.

Fewer studies reported the infection event rates; 37 study arms (25 studies) and 79 study arms (38 studies) reported 7,821 infectious events in 13,937 patients and 6,100 serious infectious events in 90,204 patients, respectively.

Table 2 a. Pooled proportion estimates 2 b. Pooled event rate estimates

Table 2a. proportions	Number o	of infecte	ed patients			Number	Number of seriously infected patients								
	Pooled estimate	n	95% CI	I^2	Cochran's Q test(P)	Pooled estimate	n	95% CI	I^2	Cochran's Q test(P)					
All studies	0.30	260	[0.28, 0.33]	95.14	< 0.001	0.03	332	[0.03, 0.03]	91.44	< 0.001					
Study design															
RCT	0.35	211	[0.32, 0.37]	89.79	< 0.001	0.03	253	[0.02, 0.03]	38.08	0.001					
Prospective cohort	0.16	19	[0.10, 0.23]	98.89	< 0.001	0.05	18	[0.03, 0.06]	86.67	< 0.001					
Registry	0.23	3	[0.19, 0.27]	57.51	0.1	0.07 37 [0.05, 0.09] 98.43		98.43	< 0.001						
RCT+OLE	0.36	36 12 [0.21, 0.53] 94.17 < 0.001		0.04	6	[0.01, 0.10]	77.78	< 0.001							
Retrospective c.	0.10					0.06	7	[0.02, 0.19] 95.24		4 < 0.001					
Open label trial	0.18	8	[0.10, 0.32]	96.38	< 0.001	0.03	11	[0.02, 0.05]	69.62	< 0.001					
Biological target															
TNF alpha inhibitor	0.30	95	[0.26, 0.35]	96.12	< 0.001	0.03	113	[0.03, 0.04]	94.63	< 0.001					
B- cell inhibitor	0.37	24	[0.30, 0.45]	86.5	< 0.001	0.03	18	[0.02, 0.05]	61.27	0.01					
Rituximab	0.29	11	[0.20, 0.40]	96.16	< 0.001	0.06	21	[0.04, 0.09]	96.77	< 0.001					
T-cell inhibitor	0.34	12	[0.21, 0.50]	99.17	< 0.001	0.03	20	[0.02, 0.05]	95.33	< 0.001					
JAK1/3 inhibitor	0.25	10	[0.20, 0.30]	36.30	0.06	0.02	20	[0.01, 0.03]	31.6	0.48					
JAK1/2 inhibitor	0.40	12	[0.33, 0.47]	81.61	< 0.001	0.02	15	[0.02, 0.03]	0	0.96					
JAK1 inhibitor	0.32	15	[0.27, 0.37]	65.75	0.03	0.02	15	[0.012, 0.03]	0	0.76					
Pan-JAK inhibitor	0.25	4	[0.17, 0.34]	53.25	0.09	0.02	14	[0.01, 0.03]	25.85	0.88					
IL6 inhibitor	0.30	48	[0.24, 0.36]	95.33	< 0.001	0.04	59	[0.03, 0.04]	77.29	< 0.001					
IL17 inhibitor	0.26	17	[0.21, 0.31]	36.12	0.29	0.02	11	[0.01, 0.05]	9.70	0.94					
IL1 inhibitor	0.23	2	[0.04, 0.67]	85.40	0.01	0.03	7	[0.02, 0.06]	74.33	0.001					
IL23 inhibitor	0.23	2	[0.16, 0.32]	0	0.78	0.03	2	[0.01, 0.09]	0	0.36					
IL 12/IL 23 inhibitor	0.31	2	[0.18, 0.47]	62.76	0.10	0.01	2	[0, 0.07]	0	0.68					
BTK inhibitor	0.11	4	[0.08, 0.16]	3.69	0.39	0.01	4	[0.01, 0.04]	0	0.94					
SYK inhibitor	-	-	-	-	-	0.02	2	[0.01, 0.06]	0	0.63					
GM-CSF inhibitor	-	-	-	-	-	0.01	7	[0.01, 0.04]	0	1					
Table 2b. event rates	Total nun	nber of i	nfected patients	•	•	Number	of serious	sly infected patients							
	ER	n	95% CI	I^2	Cochran's Q test(P)	ER	n	95% CI	I^2	Cochran's Q test(P)					

All studies	0.92	8	[0.34, 1.50]	99.82	< 0.001	0.05	44	[0.03, 0.08]	99.44	<0.001
Study design										
RCT	-	-	-	-	-	0.03	7	[0.01, 0.086]	87.97	< 0.001
Prospective cohort	-	-	-	-	-	-	-	-	-	-
Registry	0.76	3	[0.67, 0.83]	79.03	0.01	0.07	32	[0.03, 0.11]	99.71	< 0.001
RCT+OLE	1.32	3	[0.03, 2.60]	99.75	< 0.001	0.04	4	[0.03, 0.05]	43.15	0.38
Retrospective cohort	-	-	-	-	-	-	-	-	-	-
Open label trial	-	-	-	-	-		-	-	-	-
Biological target										
TNF alpha inhibitor	-	-	-	-	-	0.05	19	[0.00, 0.10]	99.80	< 0.001
IL 6 inhibitor	0.53	5	[0.30, 0.77]	99.24	< 0.001	0.04	9	[0.03, 0.06]	94.63	< 0.001
Rituximab	-	-	-	-	-	0.09	4	[0.01, 0.18]	99	< 0.001
T cell inhibitor	-	-	-	-	-	0.07	6	[0.0, 0.17]	99.71	< 0.001
B cell inhibitor	-	-	-	-	-	0.04	5	[0.02, 0.07]	73.98	0.01

 $BTK = Bruton \ tyrosine \ kinase, \ CI = 95\% \ confidence \ interval, \ ER = pooled \ event \ rate, \ GM-CSF = granulocyte-macrophage \ colony \ stimulating \ factor, \ IL = interleukin, \ JAK = Janus \ kinase, \ n = number \ of \ study \ arms, \ RCT = randomised \ controlled \ trial, \ RCT+OLE = randomised \ controlled \ trial \ and \ open \ label \ extension, \ SYK = spleen \ tyrosine \ kinase, \ TNF = tumour \ necrosis \ factor$

Fig 3. Forest plot for 50 randomly selected RCT studies, (a) for the total number of infected patients, (b) for seriously infected patients.

95% CI = 95% confidence interval. Events = number of (seriously) infected patients. Total = total number of patients included in the study.

A forest plot visually illustrates the relationship between included studies and gives an overview of heterogeneity of individual results. For a complete overview of forest plots, see S17 Appendix.

Multivariate meta-regression

A multivariate meta-regression model was fitted using one moderator at a time to explore the association between demographic, biological/targeted therapy and methodological characteristics as potential predictors of the logit of infection prevalence in RCT studies with a follow-up duration of \leq 18 weeks, 19-38 weeks, and 39 - 60 weeks. For the purpose of readability, we included the results of the meta-regression analyses in S15 Appendix (follow-up duration of \leq 18 weeks and 19-38 weeks) and S16 Appendix (follow-up duration 39-60 weeks). A separate analysis by follow-up duration was carried out with anticipation that different sets of moderators are responsible for the heterogeneity in the three subgroups. No single moderator was found to be significant across all three groups. In both the total number of infected patients as well as in the number of seriously infected patients, the subgroup of 39-60 weeks of follow-up was the smallest and most heterogenous, with results not significantly different from other subgroups. More information on how studies are grouped based on study design and follow-up duration is available in S8 Appendix.

Type of infections

Across all biological/targeted synthetic therapy classes, upper respiratory tract (URT) infections were the most prevalent (12.7%, 95%CI 10.6-15.0), followed by genitourinary tract infections (3.5%, 95%CI 2.9-4.2) and lower respiratory tract (LRT) infections (2.2%, 95%CI 1.9-2.7). See table 3. Individual infection proportions were comparable across biological classes. TNF-alpha inhibitors were associated with an increased proportion of mycobacterial infections (0.9%, 95%CI 0.6-1.0) compared to other drug classes. Overall, the proportion of seriously infected patients was highest in rituximab users (6.7%, 95%CI 4.5-9.7). The proportion of LRT infections (3.3%, 95%CI 1.6-6.5), and skin and soft tissue infections (2.3%, 95%CI 0.4-13.4) was also relatively high in this group, as was the proportion of Herpes Zoster (11.8%, 95%CI 3.1-35.4), however, only few studies reported on these adverse events. Compared to other drug classes, tofacitinib use was associated with an increased proportion of Herpes Zoster (2.8%, 95%CI 1.3-6.0) and pneumocystis jirovecii pneumonia (PJP) (1.5%, 95%CI 0.4-4.5).

Table 3: estimated pooled proportions of the various infections across different biological classes and targeted synthetic therapies

Total TNF-alpha inhibitors IL-6 inhibitors

	The diplications																	
	Prop	95%CI	I2 (%)	k	event s	observatio ns	Prop	95%CI	I2 (%)	k	event s	observatio ns	Prop	95%CI	I2 (%)	k	event s	observati ons
Total infected patients	0.302 9	[0.2765- 0.3306]	95.14	26 0	1551 5	58789	0.303 1	[0.2604- 0.3494]	96.12	95	5725	24088	0.297 1	[0.2402- 0.3610]	95.34	48	3111	11225
Seriously infected patients	0.030 8	[0.0275- 0.0345]	91.45	33	8969	168042	0.032	[0.0271- 0.0385]	94.63	11	4829	83393	0.035 9	[0.0295- 0.0437]	77.29	59	1137	24568
URT	0.127 0	[0.1067- 0.1504]	95.79	25 2	6887	57167	0.133	[0.0997- 0.1757]	97.31	82	3193	170826	0.151 5	[0.0958- 0.2314]	95.68	42	1067	45379
LRT	0.022 9	[0.0192- 0.0274]	86.12	15 9	1607	293431	0.023 3	[0.0181- 0.0301]	89.17	67	959	43271	0.015 8	[0.0107- 0.0233]	89.17	22	246	12429
Genitourinary	0.035 4	[0.0294- 0.0425]	75.66	12 1	859	25599	0.035 6	[0.0255- 0.0495]	83.69	41	341	10020	0.038 8	[0.0278- 0.0540]	50.72	19	104	3472
Gastrointestinal	0.012 7	[0.0094- 0.0172]	71.08	67	228	19437	0.009 8	[0.0064- 0.0151]	60.49	23	77	8784	0.015 4	[0.0085- 0.0278]	61.72	13	39	3388
Skin-soft tissue	0.012	[0.0092- 0.0161]	78.83	73	377	28054	0.011	[0.0070- 0.0196]	82.96	27	150	8943	0.015	[0.0093- 0.0241]	82.24	18	168	11514
Bone and joint	0.007	[0.0050- 0.0100]	40.9	73	81	15212	0.008	[0.0065- 0.0114]	0	16	49	6205	0.005	[0.0028-0.0125]	49.27	8	23	7192
Sepsis	0.005 7	[0.0040-0.0082]	68.2	36	153	39927 40844	0.005	[0.0033-0.0094]	75.88	20	104	28321	0.007 9	[0.0034-0.0179]	59.51	5	32	6494
Mycobacterial	0.007 2 0.014	[0.0050- 0.0105]	79.98 65.15	47	254	34681	0.009 5 0.010	[0.0063-0.0143]	77.42	35	206	25426	0.005 5 0.010	[0.0039-	61.52	2	35	6412 8941
Neurological infections Fungal	7 0.008	[0.0117- 0.0184] [0.0043-	77.66	78 17	371 39	12760	6 0.007	[0.0082- 0.0136] [0.0025-	20.25 83.48	25	121	14436 10081	0.010 9 NA	[0.0067- 0.0177] NA	61.52 NA	11	64	32
r ungai Viral	0.008 8 0.018	0.0182]	7.7	24	13	4693	0.007 8 0.018	0.0238]	83.48	11	12	2554	0.012	NA [0.0040-	NA 0	3	2	32
Other	0.018 0 0.011	0.0235]	74.69	31	101	11869	0.018 8 0.008	0.0252]	0%	8	21	2901	0.012 4 0.006	0.0377]	0	4	8	1401
Other	9	0.0198]	74.09	31	101	11009	1	0.0124]	076	0	21	2901	0	0.0119]	0	4	0	1401
Herpes Zoster	0.013 9	[0.0111- 0.0174]	60.19	97	366	36058	0.010 1	[0.0078- 0.0131]	18.48	29	116	14776	0.010 6	[0.0066- 0.0172]	59.22	12	64	9122
Salmonellosis	0.002 4	[0.0009- 0.0065]	0	3	4	1664	0.002 5	[0.0006- 0.0100]	0	2	2	814	NA	NA	NA	0	2	850
PJP	0.004 8	[0.0029- 0.0079]	63.65	31	91	35134	0.003 8	[0.0024- 0.0062]	50.99	16	78	28678	0.003 2	[0.0002- 0.0587]	67.47	2	1	920
Tuberculosis	0.004 2	[0.0031- 0.0056]	49.51	95	171	53277	0.006 1	[0.0044- 0.0084]	49.48	53	157	29592	0.001 2	[0.0006- 0.0024]	0	8	5	8046

	Rituxima	ıb					Abatace	pt				Tofacitinib							
	prop	95%CI	I2 (%)	k	event	observatio ns	Prop	95%CI	12 (%)	k	event s	observatio ns	Prop	95%CI	12 (%)	k	event s	observatio ns	
Total infected patients	0.2875	[0.1988- 0.3962]	96.72	8	772	4108	0.3321	[0.2723- 0.3978]	99.17	12	2117	8423	0.2459	[0.2022- 0.2956]	36.25	10	141	586	
Seriously infected patients	0.0665	[0.0450- 0.0973]	96.59	19	1323	14285	0.0335	[0.0238- 0.0469]	95.34	20	1382	30169	0.0208	[0.0144- 0.0299]	31.62	20	68	3576	
URT	0.1601	[0.1123- 0.2232]	75.69	8	180	1022	0.0887	[0.0314- 0.2264]	99.34	13	908	40098	0.0840	[0.0342- 0.1919]	96.71	21	450	3296	
LRT	0.0327	[0.0162- 0.0652]	80.21	11	51	2398	0.0165	[0.0076- 0.0352]	92.5	13	141	8606	0.0244	[0.0140- 0.0421]	59.78	12	48	2290	
Genitourinar y	0.0452	[0.0350- 0.0581]	0	6	57	1306	0.0140	[0.0053- 0.0361]	55.7	7	72	3659	0.0325	[0.0185- 0.0566]	65.48	6	45	1550	
Gastrointesti nal	0.0080	[0.0014- 0.0454]	38.57	2	2	359	0.0037	[0.0016- 0.0083]	34.56	6	11	3390	0.0192	[0.0061- 0.0585]	58.95	7	11	999	
Skin-soft tissue	0.0231	[0.0036- 0.1349]	82.01	4	7	569	0.0058	[0.0034- 0.0099]	8	6	13	2484	0.0097	[0.0036- 0.0264]	38.4	3	7	778	
Bone and joint	NA	NA	NA	< 1	NA	NA	0.0031	[0.0010- 0.0095]	0	2	3	996	NA	NA	NA	<1	1	201	
Sepsis	NA	NA	NA	< 1	6	2484	0.0034	[0.0013- 0.0090]	0	2	4	1372	0.0057	[0.0018- 0.0176]	0	3	3	647	
Mycobacteria l	NA	NA	NA	< 1	1	2484	0.0037	[0.0005- 0.0261]	82.23	4	7	4595	0.0060	[0.0016- 0.0218]	20.98	2	3	598	
Neurological infections	NA	NA	NA	< 1	2	12	0.0297	[0.0035- 0.2087]	81.76	6	43	4200	0.0293	[0.0135- 0.0624]	80.58	11	67	2174	
Fungal	0.0035	[0.0015- 0.0085]	0	2	5	1469	0.0047	[0.0018- 0.0125]	0	2	4	881	NA	NA	NA	<1	NA	NA	
Viral	0.0109	[0.0015- 0.0761]	92.03	2	NA	NA	NA	NA	NA	<1	NA	NA	NA	NA	NA	<1	NA	NA	
Other	0.0038	[0.0010- 0.0145]	46.01	4	4	1966	0.0087	[0.0063- 0.0119]	0	3	38	4477	0.0257	[0.0172- 0.0384]	0	8	23	928	
Herpes Zoster	0.1176	[0.0314- 0.3538]	5.97	2	2	25	0.0087	[0.0063- 0.0119]	0	3	43	4356	0.0282	[0.0131- 0.0597]	77.67	13	67	2280	
Salmonellosis	NA	NA	NA	< 1	NA	NA	0.0101	[0.0075- 0.0136]	0	3	0	0	NA	NA	NA	<1	NA	NA	
PJP	NA	NA	NA	< 1	NA	NA	NA	NA	NA	<1	6	4719	0.0145	[0.0042- 0.0488]	0	5	2	209	
Tuberculosis	NA	NA	NA	< 1	1	2484	0.0019	[0.0007- 0.0054]	29.26	4	3	7973	0.0032	[0.0009- 0.0110]	27.13		3	1869	

Events= number of infected patients, K= selected number of included studies, LRT= lower respiratory tract, NA = not available, Observations = total number of patients in included studies, PJP= Pneumocystits jirovecii pneumonia, Prop= pooled proportion of (seriously) infected patients, URT= upper respiratory tract, 95%CI = 95% confidence interval. Herpes Zoster infections are included in neurological infections, salmonellosis in of gastrointestinal infections, PJP in lower respiratory tract infections and tuberculosis in mycobacterial infections.

Case reports and series

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

The final selection yielded 372 articles in this category, comprising 503 cases and 509 identified micro-organisms. Most articles originated in the US (83, 22.3%) and Japan (77, 20.7%). Described patients were mostly female (66.8%), with a mean age of 61 years. Most described patients (398, 82%) used TNF-alpha inhibitors (details in S18 Appendix). The median onset of an infectious adverse event was 9 months after start of biological/targeted therapy (interquartile range (IQR) 3-24). Of all reported pathogens, 326 (64%) were bacterial (of which 143 mycobacterial infections), 19.4% (99) fungal, 7.9% (40) parasitic and 8.6% (44) viral (see S19 Appendix and S20 Appendix). Overall, the most frequently reported infections (187, 32%) occurred in the lower respiratory tract (LRT). The most frequently reported pathogens were Mycobacterium tuberculosis (85, 16.7% of pathogens), nontuberculous mycobacteria (50, 9.8%), Pneumocystis jirovecii (28, 5.5%), Salmonella spp (28, 5.5%), Listeria monocytogenes (24, 4.7%), Histoplasma capsulatum (22, 4.3%%) and Leishmania spp (21, 4.1%). The largest proportion of these infections were reported in TNFalpha inhibitor users, who are known to have difficulty clearing mycobacterial and intracellular bacterial infections. A relatively high number of viral (38%) and fungal (31%) infections were reported in abatacept users, however, absolute numbers were low. Relatively few fungal infections were reported in interleukin antagonist users (2, 3.6%), conversely, a relatively high number of other than intracellular bacterial infections was reported. This was also true for rituximab. Only three infections were reported in JAK-inhibitors, all fungal; see S20 Appendix.

Discussion

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

We performed a scoping review and meta-analysis with meta-regression to create an overview of and identify risk factors for infectious complications of biological and targeted synthetic therapies in RA patients. We report upon the combined results of 242 studies (trials/registries) with in total 293,431 included patients. To the best of our knowledge, this is the largest meta-analysis on infections in biological and targeted synthetic drug use in RA patients to date. We found a very high between-study heterogeneity across all analyses. We presume this was not only caused by differences in methodology, but also by differences in infectious adverse event reporting due to a lack of standardised definitions for non-serious infections and therefore variable interpretations. Furthermore, the registration of infectious adverse events during a clinical trial is in itself subject to some degree of bias and inconsistency [29] [30] [31]. Standardised definitions would reduce heterogeneity, as illustrated by a lower I^2 value in the pooled proportion of seriously as opposed to total infected patients (see Fig 2): only a definition of serious infection is currently available. We tried to mitigate this effect by grouping individual infections by the affected organ system. These shortcomings are important to consider when interpreting the results of this review, and of future studies as well. Our data show non-serious infections to be the most prevalent infectious adverse events during biological or targeted synthetic drug use in RA, with 30% of patients being affected at some point in their treatment (vs. 2-3% being affected by a serious infection). Exotic and opportunistic infections, often the subject of the 372 identified case reports/series (containing 503 individual cases), were (very) rare in trials and cohort studies, indicating a poor

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

reflection of the real-world prevalence/incidence. The upper respiratory tract, skin and soft tissues and urinary tract were most frequently affected in non-serious infections in the studies [16, 32]. Infections frequently led to treatment discontinuation, for which their recurrent nature may be more important than their severity [33]. Furthermore, recurrent infections are associated with a high patient-experienced burden and socioeconomic costs[34-38]. However, only few studies have made the occurrence of non-serious infections and their potential implications for treatment and quality of life in patients a priority[16, 32]. In all studies, TNF-alpha inhibitors were the most frequently administered drugs. We found only a few differences in pooled proportions of individual infections across various biological classes. JAK-inhibitor users had an increased proportion of Herpes Zoster and PJP, which is consistent with existing literature[39]. The proportion of mycobacterial infections was higher in TNF-alpha inhibitor users at 0.6% (95%CI 0.4-0.8) (see Table 3), however, these results were pooled from studies that in many cases excluded patients with a history of TB. Furthermore, 79% of studies took place in North America and/or Europe, where TB is not prevalent, and 89% of participants were Caucasian. As for the case reports, the majority originated in the US (83, 22%), Japan (21%) or France (39, 10%). This geographical spread of studies is most likely a reflection of the biological/targeted drug consumption, which is correlated with accessibility, that is not equally distributed around the world[40]. Therefore, little is known about the risks for infectious complications were these drugs to be used more in populations where other, 'exotic', infections are prevalent. As for predictive risk factors, we found no moderator that was significant across all three RCT subgroups for the total number of infected patients. However, several moderators were significant in one subgroup: corticosteroids below 18 weeks of follow-up, and RA duration, mean number of prior csDMARDs, leflunomide use, biological target and the use of one prior biological between 18-38 weeks of follow-up. In the above-38-week-follow-up group, no moderator was

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

identified as significant; this was the most heterogenous group. Corticosteroids, leflunomide use, a longer RA duration and a high number of prior csDMARDs were previously associated with an increased risk of serious infection, and prior biological use seemed to decrease this risk [10, 41-45]. Previous studies also show differences in risks for serious infections between different biologicals [12]. Interestingly, though prior literature shows a dosedependent effect of corticosteroids on the occurrence of serious infections, we could not confirm this. This may be explained by the exclusion of patients using high-dose corticosteroids from most RCTs and by the relatively short duration of corticosteroid therapy. When looking at seriously infected patients only (table 3), mean ESR at baseline seemed to significantly correlate with an increased proportion of seriously infected patients. This also has been found in one previous study[43]. As most included studies were RCTs (of which a significant number excluded patients with comorbidities or recurrent or chronic infections, see S12 Appendix), it is unclear to what extent our findings can be extrapolated to real-world settings in which patients have multiple comorbidities and use many different immunomodulators. This is a limitation of our study. The broad scope is without doubt this study's greatest strength. This enabled us to analyse information on all aspects of infectious complications of biological/synthetic targeted treatment in RA, using different study designs that complement each other's limitations. This review includes not only pooled proportions of the total number of (seriously) infected patients, but also proportions of patients contracting specific infections, and an analysis on potential predictors of infectious adverse events. The addition of case reports provides information on various rare serious infections and their causative pathogens, data that are generally not available from RCT studies.

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

In conclusion, non-serious infections outnumbered serious infections by 10:1 in RA patients using biological/targeted synthetic therapies, however, only little attention has been paid to them in existing literature. None of the risk factors for developing infections that were previously identified in separate studies were consistently confirmed in our meta-analysis. Further prospective research is needed using uniform infectious adverse event registration. **Funding** This research received no funding. **Author contributions** BB – conception and design, data acquisition, article selection, data analysis, writing of manuscript BG – data analysis, writing of manuscript EP – critical revision of manuscript KD - critical revision of manuscript BK - critical revision of manuscript JM – conception and design, article selection, critical revision of manuscript EV – conception and design, article selection, critical revision of manuscript **Disclosures** All authors declare no competing interests. Ethics approval This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Data availability

All data generated or analysed during this study are included in this published article/as supplementary information files. All included articles are publicly available.

Prior presentation

An abstract of this research was presented in poster form at the European Society for Immunodeificiencies (ESID), 12-15 October 2022, Gothenburg, Sweden.

References

- 490 1. Uddin J, Kraus AS, Kelly HG. Survivorship and death in rheumatoid arthritis. Arthritis
- 491 Rheum. 1970;13(2):125-30. Epub 1970/03/01. doi: 10.1002/art.1780130204. PubMed PMID:
- 492 5421722.

- 493 2. ICH Harmonised Tripartite Guideline Post-Approval Safety Data Management:
- 494 Definitions and Standards for Expedited Reporting E2D. 2003.
- 495 3. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid
- arthritis, with its comorbidity and treatment. Rheumatology (Oxford). 2013;52(1):53-61.
- 497 Epub 2012/11/30. doi: 10.1093/rheumatology/kes305. PubMed PMID: 23192911.
- 498 4. Leombruno J. The challenges of quantifying the risk of serious infection with tumor
- 499 necrosis factor antagonist therapy. J Rheumatol. 2010;37(5):887-9. Epub 2010/05/05. doi:
- 500 10.3899/jrheum.100251. PubMed PMID: 20439519.
- 501 5. Løppenthin K, Esbensen BA, Østergaard M, Ibsen R, Kjellberg J, Jennum P. Morbidity
- and mortality in patients with rheumatoid arthritis compared with an age- and sex-matched
- control population: A nationwide register study. J Comorb. 2019;9:2235042X19853484-
- 504 2235042X. doi: 10.1177/2235042X19853484. PubMed PMID: 312111114.
- 6. Gabriel SE. Why do people with rheumatoid arthritis still die prematurely? Annals of
- the rheumatic diseases. 2008;67 Suppl 3(Suppl 3):iii30-iii4. doi: 10.1136/ard.2008.098038.
- 507 PubMed PMID: 19022810.
- 508 7. Listing J, Kekow J, Manger B, Burmester G-R, Pattloch D, Zink A, et al. Mortality in
- 509 rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα
- inhibitors and rituximab. Annals of the Rheumatic Diseases. 2015;74(2):415. doi:
- 511 10.1136/annrheumdis-2013-204021.
- 512 8. Mehta B, Pedro S, Ozen G, Kalil A, Wolfe F, Mikuls T, et al. Serious infection risk in
- 513 rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal
- diseases: a US national cohort study. RMD Open. 2019;5(1):e000935. doi:
- 515 10.1136/rmdopen-2019-000935.
- 516 9. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in
- 517 rheumatoid arthritis. Arthritis Rheum. 2002;46(9):2294-300. Epub 2002/10/02. doi:
- 518 10.1002/art.10529. PubMed PMID: 12355476.
- 519 10. Salmon JH, Gottenberg JE, Ravaud P, Cantagrel A, Combe B, Flipo RM, et al.
- 520 Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with
- 521 abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA)
- 522 registry. Ann Rheum Dis. 2016;75(6):1108-13. Epub 2015/06/07. doi: 10.1136/annrheumdis-
- 523 2015-207362. PubMed PMID: 26048170.
- 524 11. Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of
- hospitalized infection in patients with rheumatoid arthritis. J Rheumatol. 2008;35(3):387-93.
- 526 PubMed PMID: rayyan-126007655.
- 527 12. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, et
- 528 al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane
- 529 Database Syst Rev. 2011;2011(2):Cd008794. Epub 2011/02/18. doi:
- 530 10.1002/14651858.CD008794.pub2. PubMed PMID: 21328309; PubMed Central PMCID:
- 531 PMCPMC7173749 Savient; consultant fee from Savient, URL Pharma, Novartis and Takeda.
- 532 GW: research grant and consultant fee from Bristol-Myers Squibb; consultant fees from
- 533 Abbott, Amgen, UCB; Data Safety Monitoring for Novartis. RC: has received consulting fees,

- 534 honoraria, research or institutional support, educational grants, equipment, services or
- 535 expenses from: Abbott, Astellas Pharma, Axellus, Bristol-Myers Squibb, Cambridge
- Nutritional Foods, Centocor, DSM Nutritional Products, Hypo-Safe, MSD, MundiPharma,
- 537 NorPharma, Pharmavie, Pfizer, Roche, Sanofi-Aventis, Scandinavian Clinical Nutrition. ETG:
- none NS: none JKM: none Filippini: none DF: none Lopes: none La Mantia: none Guyatt: in
- the last 5 years, Dr Guyatt has received grant funding from Pfizer, Lotte and John Hecht
- 540 Foundation, Bristol-Myers-Squibb, and Astra Zeneca. Dr Guyatt has also received
- consultation fee from Up-To-Date and Eli Lilly Canada. To our knowledge, none of these are
- conflicted with the subject matter of this submission. Lunn: honoraria from Baxter in
- relation to advisory boards on the use of IVIG. LM: none Schmitt: research grant from
- 544 Wyeth. PT: grants/honoraria from Bristol Myers, Chiltern International, and UCB RB:
- 545 honoraria for the 3e initiative in 2010 funded by Abbott; Principal Investigator for the
- 546 Australian Rheumatology Association Database (ARAD) The Australian Rheumatology
- 547 Association has received unrestricted educational grants from Abbott, Amgen, Roche and
- 548 Wyeth for ARAD. JR: none SH: none TW: none HS: none RJ: none CC: none.
- 549 13. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of
- rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant
- increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum.
- 552 2003;48(8):2122-7. PubMed PMID: rayyan-126007962.
- 553 14. Chan MJ, Wen YH, Huang YB, Chuang HY, Tain YL, Lily Wang YC, et al. Risk of
- tuberculosis comparison in new users of antitumour necrosis factor- α and with existing
- disease-modifying antirheumatic drug therapy. J Clin Pharm Ther. 2018;43(2):256-64. Epub
- 556 2017/11/10. doi: 10.1111/jcpt.12644. PubMed PMID: 29119581.
- 557 15. Zhang Z, Fan W, Yang G, Xu Z, Wang J, Cheng Q, et al. Risk of tuberculosis in patients
- 558 treated with TNF- α antagonists: a systematic review and meta-analysis of randomised
- 559 controlled trials. BMJ Open. 2017;7(3):e012567. PubMed PMID: rayyan-126007672.
- 560 16. Dao KH, Herbert M, Habal N, Cush JJ. Nonserious infections: should there be cause
- 561 for serious concerns? Rheum Dis Clin North Am. 2012;38(4):707-25. Epub 2012/11/10. doi:
- 562 10.1016/j.rdc.2012.08.016. PubMed PMID: 23137578.
- 563 17. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA
- 564 Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med.
- 565 2018;169(7):467-73. Epub 2018/09/05. doi: 10.7326/m18-0850. PubMed PMID: 30178033.
- 566 18. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan a web and mobile
- 567 app for systematic reviews. . Systematic Reviews. 2016;5(210). doi: DOI: 10.1186/s13643-
- 568 016-0384-4.
- 569 19. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities
- 570 (MedDRA). Drug Saf. 1999;20(2):109-17. Epub 1999/03/19. doi: 10.2165/00002018-
- 571 199920020-00002. PubMed PMID: 10082069.
- 572 20. Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package.
- 573 21. Ebert MHaPCaTFaDD. dmetar: Companion R Package For The Guide 'Doing Meta-
- 574 Analysis in R'. 2019.
- 575 22. Wickham H. ggplot 2: Elegant Graphics for Data Analysis: Springer-Verlag New York;
- 576 2016.
- 577 23. Warton DI, Hui FKC. The arcsine is asinine: the analysis of proportions in ecology.
- 578 Ecology. 2011;92(1):3-10. doi: https://doi.org/10.1890/10-0340.1.

- 579 24. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-
- 580 analyses. Bmj. 2003;327(7414):557-60. Epub 2003/09/06. doi: 10.1136/bmj.327.7414.557.
- 581 PubMed PMID: 12958120; PubMed Central PMCID: PMCPMC192859.
- 582 25. Cochran WG. The Combination of Estimates from Different Experiments. Biometrics.
- 583 1954;10(1):101-29. doi: 10.2307/3001666.
- 584 26. Jackson D. Confidence intervals for the between-study variance in random effects
- 585 meta-analysis using generalised Cochran heterogeneity statistics. Research Synthesis
- 586 Methods. 2013;4(3):220-9. doi: https://doi.org/10.1002/jrsm.1081.
- 587 27. Geissbühler M, Hincapié CA, Aghlmandi S, Zwahlen M, Jüni P, da Costa BR. Most
- 588 published meta-regression analyses based on aggregate data suffer from methodological
- 589 pitfalls: a meta-epidemiological study. BMC Medical Research Methodology.
- 590 2021;21(1):123. doi: 10.1186/s12874-021-01310-0.
- 591 28. Higgins JPT, Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M., & Welch, V.,
- editor. Cochrane Handbook for Systematic Reviews of Interventions.: Wiley-Blackwell; 2019.
- 593 29. Schroll JB, Maund E, Gøtzsche PC. Challenges in coding adverse events in clinical
- trials: a systematic review. PLoS One. 2012;7(7):e41174. Epub 2012/08/23. doi:
- 595 10.1371/journal.pone.0041174. PubMed PMID: 22911755; PubMed Central PMCID:
- 596 PMCPMC3401103.
- 597 30. Maund E, Tendal B, Hróbjartsson A, Lundh A, Gøtzsche PC. Coding of adverse events
- of suicidality in clinical study reports of duloxetine for the treatment of major depressive
- 599 disorder: descriptive study. Bmj. 2014;348:g3555. Epub 2014/06/06. doi:
- 600 10.1136/bmj.g3555. PubMed PMID: 24899651; PubMed Central PMCID: PMCPMC4045315
- at www.icmje.org/coi/disclosure.pdf (available on request from the corresponding author)
- and declare: this study is part of a PhD funded by Rigshospitalets Forskningsudvalg; no
- financial relationships with any organisations that might have an interest in the submitted
- work in the previous three years; no other relationships or activities that could appear to
- 605 have influenced the submitted work.
- 606 31. Brown EG. Methods and pitfalls in searching drug safety databases utilising the
- 607 Medical Dictionary for Regulatory Activities (MedDRA). Drug Saf. 2003;26(3):145-58. Epub
- 608 2003/02/13. doi: 10.2165/00002018-200326030-00002. PubMed PMID: 12580645.
- 609 32. Bechman K, Halai K, Yates M, Norton S, Cope AP, Hyrich KL, et al. Nonserious
- 610 Infections in Patients With Rheumatoid Arthritis: Results From the British Society for
- 611 Rheumatology Biologics Register for Rheumatoid Arthritis. Arthritis Rheumatol.
- 612 2021;73(10):1800-9. Epub 2021/04/13. doi: 10.1002/art.41754. PubMed PMID: 33844458.
- 613 33. Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A. Comparison of drug
- retention rates and causes of drug discontinuation between anti-tumor necrosis factor
- agents in rheumatoid arthritis. Arthritis Rheum. 2009;61(5):560-8. Epub 2009/05/01. doi:
- 616 10.1002/art.24463. PubMed PMID: 19405000.
- 617 34. Wagenlehner F, Wullt B, Ballarini S, Zingg D, Naber KG. Social and economic burden
- of recurrent urinary tract infections and quality of life: a patient web-based study (GESPRIT).
- 619 Expert Rev Pharmacoecon Outcomes Res. 2018;18(1):107-17. Epub 2017/07/25. doi:
- 620 10.1080/14737167.2017.1359543. PubMed PMID: 28737469.
- 621 35. Linder JA, Atlas SJ. Health-related quality of life in patients with sinusitis. Curr Allergy
- 622 Asthma Rep. 2004;4(6):490-5. Epub 2004/10/07. doi: 10.1007/s11882-004-0017-1. PubMed
- 623 PMID: 15462717.
- 624 36. François M, Hanslik T, Dervaux B, Le Strat Y, Souty C, Vaux S, et al. The economic
- burden of urinary tract infections in women visiting general practices in France: a cross-

- 626 sectional survey. BMC Health Serv Res. 2016;16(a):365. Epub 2016/08/11. doi:
- 627 10.1186/s12913-016-1620-2. PubMed PMID: 27507292; PubMed Central PMCID:
- 628 PMCPMC4977873.
- 629 37. Birnbaum HG, Morley M, Greenberg PE, Colice GL. Economic burden of respiratory
- infections in an employed population. Chest. 2002;122(2):603-11. Epub 2002/08/13. doi:
- 631 10.1378/chest.122.2.603. PubMed PMID: 12171839.
- 632 38. Wahid NW, Smith R, Clark A, Salam M, Philpott CM. The socioeconomic cost of
- 633 chronic rhinosinusitis study. Rhinology. 2020;58(2):112-25. Epub 2020/03/17. doi:
- 634 10.4193/Rhin19.424. PubMed PMID: 32172284.
- 635 39. Sunzini F, McInnes I, Siebert S. JAK inhibitors and infections risk: focus on herpes
- coster. Ther Adv Musculoskelet Dis. 2020;12:1759720x20936059. Epub 2020/07/14. doi:
- 637 10.1177/1759720x20936059. PubMed PMID: 32655703; PubMed Central PMCID:
- 638 PMCPMC7328488.
- 639 40. Tong X, Li X, Pratt NL, Hillen JB, Stanford T, Ward M, et al. Monoclonal antibodies
- and Fc-fusion protein biologic medicines: A multinational cross-sectional investigation of
- accessibility and affordability in Asia Pacific regions between 2010 and 2020. Lancet Reg
- 642 Health West Pac. 2022;26:100506. Epub 2022/07/06. doi: 10.1016/j.lanwpc.2022.100506.
- PubMed PMID: 35789824; PubMed Central PMCID: PMCPMC9249810.
- 644 41. Lang VR, Englbrecht M, Rech J, Nüsslein H, Manger K, Schuch F, et al. Risk of
- infections in rheumatoid arthritis patients treated with tocilizumab. Rheumatology (Oxford).
- 646 2012;51(5):852-7. Epub 2011/08/26. doi: 10.1093/rheumatology/ker223. PubMed PMID:
- 647 21865281.
- 648 42. Morel J, Constantin A, Baron G, Dernis E, Flipo RM, Rist S, et al. Risk factors of serious
- infections in patients with rheumatoid arthritis treated with tocilizumab in the French
- 650 Registry REGATE. Rheumatology (Oxford). 2017;56(10):1746-54. Epub 2017/09/29. doi:
- 651 10.1093/rheumatology/kex238. PubMed PMID: 28957557.
- 652 43. Favalli EG, Desiati F, Atzeni F, Sarzi-Puttini P, Caporali R, Pallavicini FB, et al. Serious
- infections during anti-TNFalpha treatment in rheumatoid arthritis patients 2009 2009-Jan.
- 654 266-73 p.

- 655 44. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of
- 656 hospitalization for pneumonia: associations with prednisone, disease-modifying
- antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum.
- 658 2006;54(2):628-34. PubMed PMID: rayyan-126007950.
- 659 45. Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, Nagasawa H, et al. Time-dependent
- 660 increased risk for serious infection from continuous use of tumor necrosis factor antagonists
- over three years in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken).
- 662 2012;64(8):1125-34. Epub 2012/03/17. doi: 10.1002/acr.21666. PubMed PMID: 22422487.

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

S17 Appendix. Additional forest plots

Supporting information S1 Appendix. Search strategy and terms S2 Appendix. Flowchart of study in- and exclusion S3 Appendix. Empty database format for RCTs, prospective observational studies, registries, open label studies, open label extension studies and retrospective observational studies S4 Appendix. Empty database format for case reports S5 Appendix. Studies making use of the same databases: inclusion, exclusion and reasoning S6 Appendix. RCTs and extension studies: inclusion, exclusion and reasoning S7 Appendix. Composition of infection composite variables S8 Appendix. Subgroup construction S9 Appendix. Variable selection S10 Appendix. Multivariate meta-regression of the total number of infected patients by study design S11 Appendix. Creation of RA severity composite variable S12 Appendix. Creation of exclusion criteria composite variable S13 Appendix. Characteristics of included trials S14 Appendix. Geographical location of trials and case reports S15 Appendix. Multivariate meta-regression for the total number of (seriously) infected patients in RCT studies with a follow-up duration of 18 weeks or less and between 19-38 weeks S16 Appendix. Multivariate meta-regression for the total number of (seriously) infected patients in RCTs with a follow-up duration of 38-60 weeks

691 S18 Appendix. Characteristics of case reports

692

693

694

S19 Appendix. List of identified micro-organisms in case reports

S20 Appendix. Figures related to the analysis of the case reports





